- Companies
- Calysta
Calysta Valuation, Funding & Investors
Calysta is valued at $30M as of January 2015.
Last Calysta valuation
$30M
Series B · Jan 2015
Last Calysta funding round
Undisclosed stage
Amount undisclosed · Jan 2024
Cumulative funding Calysta raised
$212M
across 10 funding rounds
Key investors in Calysta
Pangaea Ventures
Walden Riverwood Ventures
Municipal Employee Retirement System
Celesta Capital
Aqua Spark
Temasek
About Calysta
Calysta is a cellular agriculture company producing protein ingredients like FeedKind, FeedKind Net Zero, and Positive Protein through patented gas fermentation. Requiring no arable land or animal inputs, the platform operates from facilities powered by renewable energy to address food security via calysta.com.
Founded
2011
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$30M (Jan 2015)
Calysta Valuation
Calysta is currently valued at $30M, based on its Series B in January 2015.
The $10M round was led by Walden Riverwood Ventures, with participation from Pangaea Ventures and AquaSpark.
Calysta valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jan 2015 | Series B | $30M |
Calysta Funding History
Calysta has raised a total of $212M across 10 funding rounds.
Calysta's first fundraising round was a $3M Series A in December 2013. The most recent completed round was a undisclosed-stage round in January 2024.
Calysta funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jan 2024 | Undisclosed stage | Ocean 14 Capital | - | - | Ocean 14 Capital Fund 1 invested in Calysta during 2024, joining the shareholder register of the methane-fermentation single-cell protein producer as part of the fund's alternatives to fish protein theme. The fund recorded the transaction year as 2024 in its 2024 impact report and did not disclose the amount, the instrument, the stake acquired or the valuation, and it did not publish a standalone press release. Ocean 14 Capital said its investment included a budget allocation for the development of a decarbonisation plan at Calysta, which it agreed as a component of the impact action plan attached to the deal. The investment rationale is the direct substitution of fishmeal in aquaculture feed: Calysta estimates that FeedKind replaces fishmeal at a ratio of about 1 to 1.1, and Ocean 14 Capital calculates that each tonne of FeedKind displaces roughly 3.2 tonnes of whole wild fish. Calysta was founded in 2011 and ferments methane with naturally occurring microorganisms to make a 68 percent crude protein feed ingredient that requires negligible land and water. Its first industrial plant was built in China through Calysseo, a 50:50 joint venture with the animal nutrition group Adisseo, with nameplate capacity of 20,000 tonnes a year. FeedKind received formal approval from China's agriculture ministry for use in aquaculture feeds on 31 January 2024, and the joint venture produced about 1,787 tonnes during the year, displacing an estimated 1,079 tonnes of fishmeal on Calysta's share. The company has operations in the United States, the United Kingdom, Germany and China, and the joint venture employed around 160 people including factory staff and contractors. Management's case targets thirteen plants and more than 800,000 tonnes of annual capacity over time. |
| Mar 2021 | Series D | Adisseo (lead); BP Ventures (lead); Municipal Employee Retirement System; Walden Riverwood Ventures; Aqua Spark; Mitsui & Co | $39M | - | - |
| Jun 2019 | Series D | Adisseo (lead); BP Ventures (lead); Temasek; Municipal Employee Retirement System; Aqua Spark | $79M | - | Calysta is a Menlo Park, California-based company developing FeedKind, a sustainable single-cell protein alternative feed for aquaculture, livestock, and pets produced via gas fermentation of methane. The company announced a $30 million investment from BP Ventures on June 27, 2019, to support worldwide rollout of FeedKind and improve global food security amid land and water scarcity challenges. This investment included a strategic partnership for gas and power supply, with BP Ventures' David Hayes joining Calysta's board. The funding aligns with the specified investors, as BP Ventures participated, and sources note prior or concurrent involvement from heavyweights like Adisseo, Aqua-Spark, Temasek Holdings, Mitsui & Co., Cargill, Municipal Employee Retirement System of Michigan, Bessemer Trust, Walden Riverwood Ventures, and Pangaea Ventures. By mid-2019, Calysta had raised over $600 million cumulatively. FeedKind was already in production in England, with plans for multiple global plants leveraging BP's operational expertise. The investment focuses on scaling production of resource-efficient protein to address protein demand without expanding traditional agriculture. |
| May 2017 | Series D | Mitsui & Co (lead); Temasek (lead); Pangaea Ventures; Municipal Employee Retirement System; Walden Riverwood Ventures; Cargill; Aqua Spark | $40M | - | - |
| Apr 2017 | Series D | Celesta Capital (lead) | $3M | - | - |
| Feb 2016 | Series C | Cargill (lead); Municipal Employee Retirement System (lead); Pangaea Ventures; Walden Riverwood Ventures; AquaSpark | $30M | - | - |
| Dec 2015 | Series C | Celesta Capital (lead) | $3M | - | - |
| Jan 2015 | Series B | Walden Riverwood Ventures (lead); Pangaea Ventures; AquaSpark | $10M | $30M | Calysta, Inc. is a California-based biotechnology company developing sustainable protein feed ingredients through gas fermentation technology. The company produces FeedKind™, a microbial protein designed as an alternative feed ingredient for aquaculture, livestock, and pet nutrition applications. Calysta completed a $10 million Series B financing round on January 22, 2015, with a post-money valuation of $30.03 million. The round was co-led by Walden Riverwood Ventures and Aqua-Spark, with participation from Pangaea Ventures. The funding was intended to accelerate market introduction of the Microbial Protein Feed and advance development of high-value nutritional products. The company had previously raised $3 million in Series A funding from Pangaea Ventures in 2013, bringing total funding at the time of Series B to $13 million. Following this round, Calysta continued to grow through subsequent funding rounds, including a $30 million Series C in February 2016 and a $40 million Series D in 2017, ultimately establishing a manufacturing facility in Tennessee to scale production of FeedKind protein. |
| Jan 2015 | Series B | Celesta Capital (lead) | $5M | - | - |
| Dec 2013 | Series A | Pangaea Ventures (lead) | $3M | - | Calysta develops and commercializes fish and livestock nutritional products, as well as materials for use in industrial and consumer products with cost and performance advantages. The company is based in Menlo Park, CA, and operates in the specialty chemicals sector. Pangaea Ventures participated as an investor in Calysta's $10 million Series B round, alongside AquaSpark and Walden Riverwood Ventures as leads. Calysta has raised a total of $162 million across funding rounds from investors including Baruch Future Ventures, Bessemer Trust, BP Ventures, and Celesta Capital. |
Who has invested in Calysta?
12 investors have backed Calysta across its funding rounds, including Pangaea Ventures, Walden Riverwood Ventures, Municipal Employee Retirement System, Celesta Capital, Aqua Spark and Temasek.
Lead investors include Adisseo, BP Ventures, Mitsui & Co, Temasek, Celesta Capital and 4 other investors.
Calysta Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 4 | Lead | Dec 2013 | ||
| 4 | Lead | Feb 2016 | ||
| 4 | Lead | Jan 2015 | ||
| 3 | Participant | May 2017 | ||
| 3 | Lead | Jan 2015 | ||
| 2 | Lead | May 2017 | ||
| 2 | Lead | Feb 2016 | ||
| 2 | Lead | Jun 2019 | ||
| 2 | Participant | Jan 2015 | ||
| 2 | Lead | Jun 2019 | ||
This data is available for Pro users. Sign up to see all 12 Calysta investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Calysta
Calysta has acquired 1 company to date.
Last acquisition by Calysta was on May 20th 2014. Calysta acquired BioProtein A/S for undisclosed valuation.
Latest Acquisitions by Calysta
| Description | BioProtein A/S is a Norwegian biotechnology company commercializing single-cell protein produced via natural gas fermentation for animal feed. Its BioProtein technology yields high-quality protein from methane-oxidizing bacteria, suitable for aquaculture, poultry, and swine diets. Owned by the Norwegian University of Life Sciences and research institutes, the firm focuses on research from genomics to nutrition while BioProtein International AS handles global sales. Developed since the 1990s, production occurs at a demonstration plant in Norway processing 10 tons daily. |
| HQ Country | |
| HQ City | Stavanger |
| Deal Date | 20 May 2014 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Calysta acquisitions and their M&A valuation multiples. Start Free Trial | |
Calysta Competitors
Calysta competitors include listed companies like Blue Biofuels and Bioceres, and private ones like Integriculture, Rubi Laboratories, Pow.bio and Vestaron.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $30M | - | ||
| Private | - | - | $31M | - | ||
| Private | - | - | $28M | - | ||
| Private | - | - | $27M | - | ||
| Publicly listed | - | ($3M) | $33M | - | ||
| Publicly listed | $333M | ($10M) | $24M | 1.1x |
Calysta Public Comps
Calysta is still privately-owned, but its public comps include Blue Biofuels, Bioceres, Eden Research, Genvor, Dyadic, Desert Control, WooGene B&G, Amoeba, Nutriplant and Plant Advanced Technologies.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | ($3M) | - | - | (13.2x) | - | |||
| $333M | ($10M) | 0.8x | 1.1x | (28.0x) | 11.3x | |||
| $6M | ($2M) | 3.5x | 2.8x | (9.0x) | (11.0x) | |||
| - | ($6M) | - | - | (3.4x) | - | |||
| $1M | ($7M) | 15.6x | 3.5x | (2.7x) | - | |||
| $278K | ($8M) | 45.9x | - | (1.6x) | - | |||
| $40M | $3M | 1.2x | - | 14.6x | - | |||
| - | ($7M) | - | 9.9x | (8.5x) | (15.7x) | |||
This data is available for Pro users. Sign up to see all Calysta competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Calysta
| When was Calysta founded? | Calysta was founded in 2011. |
| Where is Calysta headquartered? | Calysta is headquartered in San Francisco, CA, United States. |
| Is Calysta publicly listed? | No, Calysta is a private, VC-backed company. |
| What is Calysta's valuation? | Calysta was last valued at $30M in its Series B in January 2015. |
| How much funding has Calysta raised? | Calysta has raised $212M across 10 funding rounds. |
| What was Calysta's last funding round? | Calysta's last funding round was a undisclosed-stage round in January 2024. |
| Who are Calysta's investors? | Calysta's investors include Pangaea Ventures, Municipal Employee Retirement System, Walden Riverwood Ventures, Aqua Spark, Celesta Capital, Temasek, Cargill, BP Ventures, AquaSpark, Adisseo and 2 others. |
| Which companies are comparable to Calysta? | Companies comparable to Calysta include Integriculture, Rubi Laboratories, Pow.bio, Vestaron, Blue Biofuels and Bioceres. |
| How many companies has Calysta acquired? | Calysta has acquired 1 company, including BioProtein A/S. |
See companies similar to Calysta
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




